{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:50:23Z","timestamp":1789159823533,"version":"build-2803163510"},"reference-count":38,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    High\u2010dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a therapeutic option for patients with relapsed follicular lymphoma (FL). The clinical characteristics and outcomes of FL relapse after ASCT in the rituximab era have not yet been fully elucidated. We retrospectively reviewed 414 FL patients treated with ASCT between 2000 and 2014 in four hematology departments. All patients received rituximab as a first\u2010line treatment. We specifically analyzed the clinical characteristics, treatment strategies at relapse, and outcomes of 95 patients (23%) who relapsed after ASCT. The patients (median age, 57\u2009y) received a median of two lines of therapy (range, 2\u20106) prior to ASCT, with 92% in complete response (CR) or partial response (PR) before ASCT. Histological transformation at relapse after ASCT was observed in 20% of the patients. Treatment at relapse after ASCT consisted of chemotherapy with or without rituximab (n = 45\/90, 50%), targeted agents (18%), rituximab monotherapy (14%), or consolidation allogeneic transplantation after induction chemotherapy (12%) and radiotherapy (6%). After relapse, the median progression\u2010free survival (PFS) and overall survival (OS) were 1\u2009year (95% CI, 0.541\u20101.579) and 5.5\u2009years (95% CI, 1.910\u20109.099), respectively. In the multivariate analysis, histological transformation (HT) was associated with OS (\n                    <jats:italic>P<\/jats:italic>\n                    = .044; HR 2.439; 95% CI, 1.025\u20105.806), and a high FLIPI score at relapse was associated with PFS (\n                    <jats:italic>P<\/jats:italic>\n                    = .028; HR 2.469; 95% CI, 1.104\u20105.521). This retrospective study showed that the period of PFS of patients who relapsed after ASCT is short. A biopsy should be performed for these patients to document the HT. Our results indicate that new treatment strategies will need to be developed for these patients.\n                  <\/jats:p>","DOI":"10.1002\/hon.2713","type":"journal-article","created":{"date-parts":[[2020,1,18]],"date-time":"2020-01-18T08:34:50Z","timestamp":1579336490000},"page":"137-145","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era"],"prefix":"10.1002","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8264-822X","authenticated-orcid":false,"given":"Pierre","family":"Sesques","sequence":"first","affiliation":[{"name":"Department of Hematology, Centre Hospitalier Lyon Sud Universit\u00e9 Claude Bernard Lyon 1  Pierre\u2010B\u00e9nite France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"Bourcier","sequence":"additional","affiliation":[{"name":"Department of Hematology Nantes University Hospital, CHU of Nantes and CHD Vend\u00e9e  La Roche\u2010sur\u2010Yon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Golfier","sequence":"additional","affiliation":[{"name":"Department of Hematology Dijon University Hospital  Dijon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Lebras","sequence":"additional","affiliation":[{"name":"Department of Hematology Centre L\u00e9on B\u00e9rard  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Nicolas\u2010Virelizier","sequence":"additional","affiliation":[{"name":"Department of Hematology Centre L\u00e9on B\u00e9rard  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Hacini","sequence":"additional","affiliation":[{"name":"Department of Hematology Centre Hospitalier M\u00e9tropole Savoie  Chamb\u00e9ry France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Claire","family":"Perrin","sequence":"additional","affiliation":[{"name":"Department of Hematology Centre Hospitalier Fleyriat  Bourg\u2010en\u2010Bresse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Voillat","sequence":"additional","affiliation":[{"name":"Department of Hematology Centre Hospitalier of Chalon\u2010sur\u2010Sa\u00f4ne  Chalon\u2010sur\u2010Sa\u00f4ne France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Bachy","sequence":"additional","affiliation":[{"name":"Department of Hematology, Centre Hospitalier Lyon Sud Universit\u00e9 Claude Bernard Lyon 1  Pierre\u2010B\u00e9nite France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Traverse\u2010Glehen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Centre Hospitalier Lyon Sud Universit\u00e9 Claude Bernard Lyon 1  Pierre B\u00e9nite France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Moreau","sequence":"additional","affiliation":[{"name":"Department of Pathology CHU of Nantes  Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Pathology Dijon University Hospital  Dijon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selim","family":"Ramla","sequence":"additional","affiliation":[{"name":"Department of Pathology Dijon University Hospital  Dijon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Casasnovas","sequence":"additional","affiliation":[{"name":"Department of Hematology Dijon University Hospital  Dijon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Le Gouill","sequence":"additional","affiliation":[{"name":"Department of Hematology, CHU of Nantes CRCINA INSERM team 10 Nantes Nantes University NUN Next  Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[{"name":"Department of Hematology, Centre Hospitalier Lyon Sud Universit\u00e9 Claude Bernard Lyon 1  Pierre\u2010B\u00e9nite France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Ghesqui\u00e8res","sequence":"additional","affiliation":[{"name":"Department of Hematology, Centre Hospitalier Lyon Sud Universit\u00e9 Claude Bernard Lyon 1  Pierre\u2010B\u00e9nite France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,1,30]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1323"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008399623564"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.8327"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.023"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.2.404"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr450"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0982"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3920"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404850"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.030320"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2007.06.016"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.084723"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28243"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn691"},{"issue":"6","key":"e_1_2_6_19_1","article-title":"Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long term disease control. An analysis from the Lymphoma Working Party Of the EBMT","volume":"27","author":"Robinson SP","year":"2016","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1977.1"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.2083"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.223"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12741"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds657"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.216"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1217"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.12.771"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.7163"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000905"},{"key":"e_1_2_6_36_1","unstructured":"A Phase 2 MulticenterStudy of Axicabtagene Ciloleucel in Subjects With Relapsed\/Refractory Indolent Non\u2010Hodgkin Lymphoma \u2010 Full Text View \u2010ClinicalTrials.gov[Internet]. [cited2019Apr 5]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03105336?term=car+t+cells&cond=Follicular+Lymphoma&draw=3&rank=21"},{"key":"e_1_2_6_37_1","unstructured":"Study Evaluatingthe Safety and Pharmacokinetics of JCAR017 in B\u2010cell Non\u2010Hodgkin Lymphoma (TRANSCEND\u2010NHL\u2010001) \u2010 Full Text View \u2010ClinicalTrials.gov[Internet]. [cited2019Apr 5]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02631044"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110207"},{"issue":"1","key":"e_1_2_6_39_1","first-page":"189","article-title":"Sequencing of therapies in relapsed follicular lymphoma","volume":"2018","author":"Nastoupil LJ","year":"2018","journal-title":"ASH Educ Program Book"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2713","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2713","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.2713","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2713","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T09:20:13Z","timestamp":1693732813000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,30]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1002\/hon.2713"],"URL":"https:\/\/doi.org\/10.1002\/hon.2713","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/HON.2713\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2713\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2713\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2713\/v2\/decision1","asserted-by":"object"}]},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,30]]},"assertion":[{"value":"2019-10-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}